openPR Logo
Press release

The use of Animal Models in Pre-Clinical Drug Development

09-19-2017 01:53 PM CET | Health & Medicine

Press release from: SMi Group

Superbugs and Superdrugs USA

Superbugs and Superdrugs USA

UNT Health Science Centre to lead interactive workshop at the next annual USA meeting on Superbugs and Superdrugs

SMi Group’s USA conference on Superbugs & Superdrugs is set to return to Iselin New Jersey this fall on November 13th and 14th. Not only will the next instalment in the global series feature an agenda that hones in on expert led approaches to strengthen the antibiotic pipeline, but it will also offer hands on training through a carefully selected post-conference interactive workshop taking place on November 15th.

Hosted by the UNT Health Science Centre and led by William Weiss, Director, Pre-Clinical Services; and Mark Pulse, Assistant Director; the workshop on "The Use of Animal Models in Pre-Clinical Drug Development" will focus on the transition from in vitro activity to in vivo efficacy; the choice of the right animal model for proof of concept studies; and provide examples of relevant animal models with supportive data and interpretation of results as it relates to the clinical condition.

William Weiss has extensive experience in pre-clinical microbiology research and development efforts focused on the discovery & development of new antimicrobial agents. He has worked on numerous antibacterial programs including the development of the marketed antibiotics; Suprax, Zosyn and Tygacil.

Mark Pulse has been directly involved in the development of multiple in vivo models that have included GI- and respiratory-associated infectious diseases, device-associated (biofilm) infections and pharmacokinetic studies.

Other notable speakers on the agenda will include representatives from: Janssen, BARDA, CARB-X, Pfizer, MedImmune, Visterra, Contrafect, Centauri Therapeutics, Microbiotix and Merck.

Further information on Superbugs & Superdrugs USA is available at https://www.smi-online.co.uk/pharmaceuticals/northamerica/superbugs-superdrugs-usa?utm_medium=www.superbugs-usa.com&utm_source=P-226&utm_campaign=OPENPR

Superbugs & Superdrugs USA will take place on 13th & 14th November at the Renaissance Woodbrigde Hotel in Iselin, New Jersey. Sponsored by Merck and Soligenix.

--- END ---

About SMi Group:

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

About UNT Health Science Centre

The Pre-Clinical Services group in the UNT System College of Pharmacy at the University of North Texas Health Science Center conducts industry sponsored research studies utilizing established models of both acute and chronic bacterial infections in several different animal species including pharmacokinetic/pharmacodynamic studies with bioanalytical LCMS/HPLC analysis. Infection models or protocols other than those described herein can also be develop and validated as required to meet the more specific needs of interested Sponsors. UNTHSC Pre-clinical Services together has over 35 years of direct pharmaceutical and specialized biotech experience in the performance of therapeutic efficacy models and drug discovery/development. The group utilizes this experience to guide the drug discovery process, from protocol design to implementation and analysis for compound lead selection. Studies are conducted in state-of-the-art laboratory and vivarium facilities with excellent support staff and services.

Contact Information:

For all media inquiries contact Teri Arri on Tel: +44 (0)20 7827 6162 / Email: tarri@smi-online.co.uk

2 Floor Harling House
47-51 Great Suffolk Street

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release The use of Animal Models in Pre-Clinical Drug Development here

News-ID: 726475 • Views:

More Releases from SMi Group

Exclusive Speaker Interview with AOBiome ahead of the 22nd Pain Therapeutics Conference
Exclusive Speaker Interview with AOBiome ahead of the 22nd Pain Therapeutics Con …
SMi Reports: Exclusive speaker interview with Todd Krueger at AOBiome released for the Pain Therapeutics Conference The pain therapeutics industry has grown at an exponential rate in recent years. The 22nd Annual Pain Therapeutics conference will cover the leading advances in pain therapeutics, exploring late development clinical trials, novel treatments for chronic conditions, technology collaboration treatments, using VR and Medical Devices that carry out non-invasive nerve stimulation. Industry leaders will uncover the
Exclusive Speaker Interview with Ester Lovsin Barle ahead of the 6th Annual Highly Potent Active Pharmaceutical Ingredients Conference.
Exclusive Speaker Interview with Ester Lovsin Barle ahead of the 6th Annual High …
Now in its 6th year, the Highly Potent Active Pharmaceutical Ingredients conference offers you peer-to-peer networking with industry experts including heads and directors of EHS, Occupational Hygiene, Quality Assurance and more. Taking place on 9th and 10th May in London, UK. With a key focus on expanding your community and exploring the latest developments in the industry at this two-day event, including key regulatory updates, and leading case studies from leading
FDA Keynote Speaker at SMi's 5th Annual Pharmaceutical Microbiology East Coast Conference in Boston, USA
FDA Keynote Speaker at SMi's 5th Annual Pharmaceutical Microbiology East Coast C …
SMi Group Reports: Keynote FDA speaker Dr. John Arigo, to present at the 4th Annual Pharmaceutical Microbiology East Coast, taking place in just 3 weeks' time on April 27th and 28th, 2022. With just three weeks remaining until the highly anticipated conference, SMi Group are delighted to announce a key FDA Speaker joining the 5th Annual Pharmaceutical Microbiology East Coast Conference. This event will take place on April 27th and
Group Captain (ret'd) Robert Daisley invites you to attend Air Mission Planning …
SMi Group reports: Chairman Group Captain (ret'd) Robert Daisley of the Air Mission Planning and Support Conference cordially invites experts to join the conference in London, UK in one week. With only one week remaining, SMi Group is delighted to publish an invitation letter for SMi's 13th Annual Air Mission Planning & Support Conference, taking place on the 6th and 7th April 2022 in London, UK from the conference chairman. The

All 5 Releases


More Releases for Superbugs

Antibiotics Market - Battling Superbugs: Cutting-Edge Antibiotics for Resistant …
Newark, New Castle, USA: The "Antibiotics Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors Antibiotics Market: https://www.growthplusreports.com/report/antibiotics-market/7752 This latest report researches the industry structure, sales, revenue, price and
1 week to go to SMi's 22nd Annual Superbugs & Superdrugs Conference
SMi Reports: Superbugs & Superdrugs conference taking place next week, will now be by remote access only With only 1 week remaining, the 22nd Annual Superbugs & Superdrugs Conference will reconvene on the 30 and 31 March, with remote access only. This year's global focused two-day conference pharmaceutical is for industry professionals looking to gain an in-depth knowledge of the scientific, economic, and regulatory challenges facing the critical global issue of
Interview with Martin Everett speaker at SMi's Superbugs & Superdrugs Conference
SMi Reports: An Interview with Martin Everett, Chief Scientific Officer, at Antabio, who will be speaking at SMi's highly anticipated 22nd Annual Superbugs & Superdrugs Conference on the 30th and 31st March 2020 in London. This year's global focused two-day conference pharmaceutical is for industry professionals looking to gain an in-depth knowledge of the scientific, economic, and regulatory challenges facing the critical global issue of antibiotic resistance. For interested individuals to attend
Evotec & Scynexis to lead the workshops for Superbugs & Superdrugs 2020
SMi Reports: Interactive workshop overview for SMi's 22nd Annual Superbugs & Superdrugs Conference, London in March 2020 SMi’s highly anticipated 22nd Annual Superbugs & Superdrugs Conference will commence on the 30th and 31st March 2020 and in London, UK. For this year’s conference, industry leaders and key profiles from leading pharmaceutical organisations will be brought together to discuss the strategies in place that reduce AMR, evaluate the role pharmaceutical companies and funding
SMi’s 22nd Annual Superbugs & Superdrugs Conference 2020 – Speakers Announce …
SMi Reports: the agenda and speaker overview of the upcoming SMi’s 22nd Annual Superbugs & Superdrugs Conference 2020, in London is now available to view. SMi Group is delighted to announce the return of the successful Superbugs & Superdrugs Conference for its 22nd year, taking place on 30th and 31st March 2020 at the Holiday Inn Kensington Forum in London. Antibiotics have long been one of the most important pharmaceuticals
Four weeks until SMi’s 21st Annual Superbugs & Superdrugs Conference 2019
SMi Reports: Senior industry experts will gather in London to discuss the recent advances made in combating antibiotic resistance. As the global threat of antimicrobial resistance continues to grow, the advances of modern medicines are at risk of being lost. Failure to act quickly means the spread of antibiotic-resistant bacteria could lead to increased mortality from normally minor injuries and benign infections. For this reason, the Superbugs & Superdrugs conference, taking